The purpose of the Administration, Evaluation and Planning Core is to ensure the coordination of the Dana- Farber/Harvard Cancer Center (DF/HCC) Lung Cancer SPORE components and to provide oversight and leadership of the scientific, administrative, and fiscal aspects of the SPORE.Within the DF/HCC Lung Cancer SPORE, there are several layers of oversight and evaluation. Dr. Johnson, as SPORE Director, monitors the progress of the Projects and Cores and oversees the Career Development Program (along with Drs. David Christian! and Daniel Tenen), the Developmental Research Program (along with Dr. David Kwiatkowski), and all other proposed activities. Within the DF/HCC, Dr. Johnson has the authority and resources to ensure the success of this SPORE. Our Governance Committee, made up of senior members of the DF/HCC Lung Cancer Program, meets monthly to provide immediate decision-making. Dr. Johnson will be joined by David Christiani, Professor of Medicine and Public Health, to assume the responsibility as Co-Pi of the SPORE. Dr. Christiani brings his leadership expertise in pulmonary medicine and public health to our proposed studies in lung cancer. We have a strong Internal Advisory Board, comprised o f prominent members of the Harvard Medical School community and representing the participating institutions and major cancer research disciplines. Our External Advisory Board will meet in the Boston area annually during the five-year funding cycle. The membership and functions of these committees are discussed in detail in the description of this Core.The Administration, Evaluation and Planning Core allows for the provision of stimulating intellectual activities, organization of venues for planning future research through seminars and retreats, and the oversight of research and spending. This Core also provides the tools to work with institutions inside and outside of Harvard University to leverage the considerable power of the SPORE in order to raise more research funding for lung cancer. The responsibilities of the Administration, Evaluation and Planning Core are to: 1) Select research projects and evaluate research progress;2) Foster collaborative research within the SPORE and between SPOREs;3) Integrate the Lung SPORE into the DF/HCC structure;4) Provide necessary resources and fiscal oversight and 5) Promote rapid dissemination of significant research findings and facilitate resource exchange.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA090578-10
Application #
8377871
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
2014-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
10
Fiscal Year
2012
Total Cost
$619,944
Indirect Cost
$70,272
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Xu, Yinghui; Liu, Hongliang; Liu, Shun et al. (2018) Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. Int J Cancer 143:2400-2408
Ji, Xuemei; Bossé, Yohan; Landi, Maria Teresa et al. (2018) Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. Nat Commun 9:3221
Guo, Yichen; Zhang, Ruyang; Shen, Sipeng et al. (2018) DNA Methylation of LRRC3B: A Biomarker for Survival of Early-Stage Non-Small Cell Lung Cancer Patients. Cancer Epidemiol Biomarkers Prev 27:1527-1535
Haines, Eric; Chen, Ting; Kommajosyula, Naveen et al. (2018) Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in KRAS-mutant non-small cell lung cancer. Oncotarget 9:31572-31589
Wang, Zhaoxi; Wei, Yongyue; Zhang, Ruyang et al. (2018) Multi-Omics Analysis Reveals a HIF Network and Hub Gene EPAS1 Associated with Lung Adenocarcinoma. EBioMedicine 32:93-101
Torous, Vanda F; Rangachari, Deepa; Gallant, Benjamin P et al. (2018) PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option? J Am Soc Cytopathol 7:133-141
Ferreiro-Iglesias, Aida; Lesseur, Corina; McKay, James et al. (2018) Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity. Nat Commun 9:3927
VanderLaan, Paul A; Rangachari, Deepa; Majid, Adnan et al. (2018) Tumor biomarker testing in non-small-cell lung cancer: A decade of change. Lung Cancer 116:90-95
Sofer, Tamar; Schifano, Elizabeth D; Christiani, David C et al. (2017) Weighted pseudolikelihood for SNP set analysis with multiple secondary outcomes in case-control genetic association studies. Biometrics 73:1210-1220
Rangachari, Deepa; Le, Xiuning; Shea, Meghan et al. (2017) Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy. J Thorac Oncol 12:e175-e177

Showing the most recent 10 out of 263 publications